Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity
- 1 December 1980
- journal article
- research article
- Published by Elsevier in Prostaglandins
- Vol. 20 (6), 1103-1116
- https://doi.org/10.1016/0090-6980(80)90063-5
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Exposure of platelet fibrinogen receptors by ADP and epinephrine.Journal of Clinical Investigation, 1979
- Selective Binding Site for [3H]Prostacyclin on PlateletsJournal of Clinical Investigation, 1979
- Stimulation of Endothelial Cell Prostacyclin Production by Thrombin, Trypsin, and the Ionophore A 23187Journal of Clinical Investigation, 1978
- Thrombogenic Effect of High-Dose Aspirin in RabbitsJournal of Clinical Investigation, 1978
- Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different speciesProstaglandins, 1978
- Application of light-scattering theory to the optical effects associated with the morphology of blood plateletsArchives of Biochemistry and Biophysics, 1977
- HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATIONThe Lancet, 1977
- Geometry of normal mammalian platelets by quantitative microscopic studiesBiophysical Journal, 1976
- Sodium Arachidonate Can Induce Platelet Shape Change and Aggregation Which Are Independent of the Release ReactionScience, 1976
- Rheo- and electro-optical behavior of plateletsJournal of Colloid and Interface Science, 1972